Genetic Variations of Angiotensinogen, Angiotensin Converting Enzyme, and Angiotensin Type 1 Receptor with the Risk of Pulmonary Tuberculosis
Prague Medical Report · 2024
DOI: 10.14712/23362936.2024.1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prague Medical Report, 2024. Verfasst von Hamidreza Kouhpayeh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, Iran. Hauptthemen laut MEDLINE: Peptidyl-Dipeptidase A, Tuberculosis, Pulmonary. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zahedan University of Medical Sciences.
Abstract (Originalsprache)
There is little data regarding the impact of renin-angiotensin system (RAS) gene polymorphisms on tuberculosis. The current study designed to survey the possible association between RAS polymorphisms and the risk of pulmonary tuberculosis (PTB) in a sample of the southeast Iranian population. This case-control study was done on 170 PTB patients and 170 healthy subjects. The AGT rs699 C>T, ACE rs4341 C>G and AT1R rs5186 C>A variants were genotyped using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) and ACE rs4646994 (287bp I/D) variant by PCR method. Regarding AT1R rs5186 A>C polymorphism, the findings revealed that AC genotype and C allele significantly decreased the risk of PTB (OR=0.39, 95% CI=0.22–0.67, p=0.001, and OR=0.53, 95% CI=0.25–0.72, p=0.002, C vs. A, respectively). The TC genotype and C allele of AGT rs699 T>C significantly associated with decreased the risk of PTB (OR=0.45, 95% CI=0.28–0.74, p=0.002, TC vs. TT and OR=0.51, 95% CI=0.32–0.80, p=0.005, C vs. T, respectively). The ID genotype of ACE 287bp I/D significantly increased the risk of PTB (OR=1.88, 95% CI=1.12–3.17, p=0.017). Our finding did not support an association between ACE rs4341 C>G variant and the risk of PTB. In summary, the findings revealed an association between AT1R rs5186 A>C, AGT rs699 T>C and ACE 287bp I/D polymorphisms and the risk of PTB in a sample of the southeast Iranian population. Further investigation with higher sample sizes and diverse ethnicities are required to confirm our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
- Children and Adolescent Health Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
- Genetics of Non-Communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
- Department of Genetic, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran. mohsen.taheri.gene@gmail.com.
- Genetics of Non-Communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, Iran. mohsen.taheri.gene@gmail.com.
Förderung
- Zahedan University of Medical Sciences
Zitieren
APA
Kouhpayeh, H., Naderi, M., Mohammadghasemipour, Z., Bahari, G., Elahian, N., Taheri, M., & Hashemi, M. (2024). Genetic Variations of Angiotensinogen, Angiotensin Converting Enzyme, and Angiotensin Type 1 Receptor with the Risk of Pulmonary Tuberculosis. Prague Medical Report. https://doi.org/10.14712/23362936.2024.1
Vancouver
Kouhpayeh H, Naderi M, Mohammadghasemipour Z, Bahari G, Elahian N, Taheri M, et al. Genetic Variations of Angiotensinogen, Angiotensin Converting Enzyme, and Angiotensin Type 1 Receptor with the Risk of Pulmonary Tuberculosis. Prague Medical Report. 2024. doi:10.14712/23362936.2024.1
BibTeX
@article{Kouhpayeh2024,
author = {Kouhpayeh, Hamidreza and Naderi, Mohammad and Mohammadghasemipour, Zahra and Bahari, Gholamreza and Elahian, Nastaran and Taheri, Mohsen and Hashemi, Mohammad},
title = {Genetic Variations of Angiotensinogen, Angiotensin Converting Enzyme, and Angiotensin Type 1 Receptor with the Risk of Pulmonary Tuberculosis},
journal = {Prague Medical Report},
year = {2024},
doi = {10.14712/23362936.2024.1}
}
EUVIMED